Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma <i>in vivo</i>
Elgilda Musi(Columbia University Irving Medical Center), Jack L. Arbiser(United States Department of Veterans Affairs)
Cited by 7
Related Papers
Cardiovascular disease in neurofibromatosis 1: Report of the NF1 Cardiovascular Task Force
|Genetics in Medicine|2002|398
Forty-Year Journey of Angiogenesis Translational Research
|Science Translational Medicine|2011|223
Propranolol exhibits activity against hemangiomas independent of beta blockade
|npj Precision Oncology|2019|43